Novel primary malignancies, tumor promotion in BRAF wild-type patients, hemorrhage, venous thromboembolism, cardiomyopathy, ocular toxicities, interstitial lung disease, skin toxicity, febrile reactions, hyperglycemia115. Here, BRAF is linked to venous thromboembolism.